In-Depth Analysis of Incidence and Survival of Lacrimal Gland Malignancies in the United States of America from 1995 to 2018

References

• Gündüz AK, Yeşiltaş YS, Shields CL. Overview of benign and malignant lacrimal gland tumors. Curr Opin Ophthalmol. 2018;29(5):458–468. doi:10.1097/ICU.0000000000000515
   PubMed Web of Science ®Google Scholar
• Hassan WM, Bakry MS, Hassan HM, Alfaar AS. Incidence of orbital, conjunctival and lacrimal gland malignant tumors in USA from surveillance, epidemiology and end results, 1973-2009. Int J Ophthalmol. 2016;9(12):1808–1813. doi:10.18240/ijo.2016.12.18
   PubMed Web of Science ®Google Scholar
• Weis E, Rootman J, Joly TJ, et al. Epithelial lacrimal gland tumors: pathologic classification and current understanding. Arch Ophthalmol (Chicago, Ill 1960). 2009;127(8):1016–1028. doi:10.1001/archophthalmol.2009.209
   PubMedGoogle Scholar
• Mallen-St Clair J, Arshi A, Tajudeen B, Abemayor E, St John M. Epidemiology and treatment of lacrimal gland tumors: a population-based cohort analysis. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1110–1116. doi:10.1001/jamaoto.2014.2846
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Eagle RC, Rathmell JP. Clinicopathologic review of 142 cases of lacrimal gland lesions. Ophthalmology. 1989;96(4):431–435. doi:10.1016/s0161-6420(89)32873-9
   PubMed Web of Science ®Google Scholar
• Chawla B, Kashyap S, Sen S, et al. Clinicopathologic review of epithelial tumors of the lacrimal gland. Ophthal Plast Reconstr Surg. 2013;29(6):440–445. doi:10.1097/IOP.0b013e31829f3a0c
   PubMed Web of Science ®Google Scholar
• Yeşiltaş YS, Gündüz AK, Erden E, Shields CL. Lacrimal gland tumors in Turkey: types, frequency, and outcomes. Int J Ophthalmol. 2018;11(8):1296–1302. doi:10.18240/ijo.2018.08.08
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Epstein JA, Scartozzi R, Eagle RC. Review: primary epithelial malignancies of the lacrimal gland: the 2003 Ramon L. Font lecture. Ophthal Plast Reconstr Surg. 2004;20(1):10–21. doi:10.1097/01.IOP.0000103003.87842.BB
   PubMed Web of Science ®Google Scholar
• Rasmussen P, Ralfkiaer E, Prause JU, Sjö LD, Siersma VD, Heegaard S. Malignant lymphoma of the lacrimal gland: a nation-based study. Arch Ophthalmol (Chicago, Ill 1960). 2011;129(10):1275–1280. doi:10.1001/archophthalmol.2011.270
   PubMedGoogle Scholar
• Tewari M, Choudhary S, Sherigar V, Kumar M, Shukla HS. Melanoma of the lacrimal gland: a case report. J Surg Oncol. 2012;106(6):796–797. doi:10.1002/jso.23193
   PubMed Web of Science ®Google Scholar
• Mahdi Y, Azami MA, Daoudi R, Cherradi N. Diagnostic pitfall: primary myoepithelial carcinoma of the lacrimal gland, case report and literature review. BMC Clin Pathol. 2018;18(1):1–7. doi:10.1186/s12907-018-0073-4
   PubMedGoogle Scholar
• Anesi A, Negrello S, Lucchetti D, et al. Clinical management of acinic cell carcinoma of the lacrimal gland. Case Rep Oncol. 2019;12(3):777–790. doi:10.1159/000503557
   PubMed Web of Science ®Google Scholar
• Andreoli MT, Aakalu V, Setabutr P. Epidemiological trends in malignant lacrimal gland tumors. Otolaryngol Head Neck Surg. 2015;152(2):279–283. doi:10.1177/0194599814556624
   PubMed Web of Science ®Google Scholar
• Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547–569. doi:10.1177/0962280206070621
   PubMed Web of Science ®Google Scholar
• Cho H, Howlader N, Mariotto AB, Cronin KA. Estimating relative survival for cancer patients from the SEER program using expected rates based on Ederer I versus Ederer II method. Surveillance Research Program, NCI, Technical Report. 2011;1:2011.
   Google Scholar
• NCI. Surveillance Research Program, National Cancer Institute SEER*Stat software version 8.4.0.1.
   Google Scholar
• Joinpoint Regression Program. Published online 2022.
   Google Scholar
• Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–351. doi: 10.1002/(sici)1097-0258(20000215)19:3<335:aid-sim336>3.0.co;2-z
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Zhang F, Buckman DW, Miller D, Cho H, Feuer EJ. Characterizing trends in cancer patients’ survival using the JPSurv software. Cancer Epidemiol Biomarkers Prev. 2021;30(11):2001–2009. doi:10.1158/1055-9965.EPI-21-0423.
   PubMed Web of Science ®Google Scholar
• Von Holstein SL, Therkildsen MH, Prause JU, et al. Lacrimal gland lesions in Denmark between 1974 and 2007. Acta Ophthalmol. 2013;91(4):349–354. doi:10.1111/j.1755-3768.2012.02403.x
   PubMed Web of Science ®Google Scholar
• Wright JE, Rose GE, Garner A. Primary malignant neoplasms of the lacrimal gland. Br J Ophthalmol. 1992;76(7):401–407. doi:10.1136/bjo.76.7.401.
   PubMed Web of Science ®Google Scholar
• Proia AD, Ranjit-Reeves R, Woodward JA. Lacrimal Gland Tumors. Int Ophthalmol Clin. 2018;58(2):197–235. doi:10.1097/IIO.0000000000000220.
   PubMedGoogle Scholar
• von Holstein SL, Rasmussen PK, Heegaard S. Tumors of the lacrimal gland. Semin Diagn Pathol. 2016;33(3):156–163. doi:10.1053/j.semdp.2015.10.002
   PubMed Web of Science ®Google Scholar
• Fasola CE, Jones JC, Huang DD, Le Q-T, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 gy × 2) in the treatment of orbital lymphoma. Int J Radiat Oncol. 2013;86(5):930–935. doi:10.1016/j.ijrobp.2013.04.035
   PubMed Web of Science ®Google Scholar
• von Holstein SL, Coupland SE, Briscoe D, Le Tourneau C, Heegaard S. Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological survey. Acta Ophthalmol. 2013;91(3):195–206. doi:10.1111/j.1755-3768.2012.02402.x
   PubMed Web of Science ®Google Scholar
• Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069–1080. doi:10.1111/j.1365-2133.2012.10830.x
   PubMed Web of Science ®Google Scholar
• Van Monsjou, H S, Wreesmann, V B, Van Den Brekel M W, et al. Head and neck squamous cell carcinoma in young patients. Oral Oncol. 2013;49(12):1097–1102. doi:10.1016/j.oraloncology.2013.09.001
   PubMed Web of Science ®Google Scholar
• Tse DT, Benedetto P, Dubovy S, Schiffman JC, Feuer WJ. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol. 2006;141(1):44–53. doi:10.1016/j.ajo.2005.08.068
   PubMed Web of Science ®Google Scholar
• Doddapaneni R, Tao W, Naranjo A, Nikpoor N, Tse DT, Pelaez D. Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland. Oncotarget. 2019;10(4):480–493. doi:10.18632/oncotarget.26558
   PubMedGoogle Scholar
• Tran AQ, Choi CJ, Al-Sadah Z, et al. Bilateral poorly differentiated adenocarcinoma of the lacrimal gland with tumor regression after treatment with Pembrolizumab. Ophthal Plast Reconstr Surg. 2020;36(6):e144–e147. doi:10.1097/IOP.0000000000001673
   PubMed Web of Science ®Google Scholar
• Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol (Chicago, Ill 1960). 1998;116(3):315–321. doi:10.1001/archopht.116.3.315
   PubMedGoogle Scholar
• Pickering CR, Zhou JH, Lee JJ, et al. Mutational landscape of aggressive cutaneous squamous cell CarcinomaSequencing of cSCC. Clin Cancer Res. 2014;20(24):6582–6592. doi:10.1158/1078-0432.CCR-14-1768
   PubMed Web of Science ®Google Scholar
• Lally SE, Milman T, Orloff M, et al. Mutational landscape and outcomes of conjunctival melanoma in 101 patients. Ophthalmology. 2022;129(6):679–693. doi:10.1016/j.ophtha.2022.01.016
   PubMed Web of Science ®Google Scholar